Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Carbonic anhydrase (CA) enzymes, particularly CA IX and CA XII, are vital for pH regulation in hypoxic tumors, promoting cancer cell survival and proliferation.
• These isozymes are recognized as promising therapeutic targets for developing novel anti-cancer strategies.
• Current therapeutic options targeting CA are limited, necessitating the development of new inhibitor classes.

Purpose of the Study:

• To develop and characterize a new class of carbohydrate-based small molecule inhibitors targeting carbonic anhydrase IX and XII.
• To evaluate the efficacy of these inhibitors in cell-based models mimicking the acidic tumor microenvironment.
• To identify potent inhibitors with potential for selective cancer cell targeting in vivo.

Main Methods:

• Synthesis and characterization of novel carbohydrate-based small molecules.
• Enzyme inhibition assays to determine inhibitory constants (K(i)) against CA IX and XII.
• Cell-based assays using models of acidic tumor microenvironments to assess inhibitor efficacy.
• Evaluation of inhibitor effects on cancer cell survival and proliferation.

Main Results:

• Development of a new class of carbohydrate-based CA inhibitors.
• Several compounds demonstrated potent inhibition of CA IX and XII with low nanomolar K(i) values (5.3-11.2 nM).
• Compounds 5 and 17 were identified as effective inhibitors that block CA IX-mediated cancer cell survival in acidic conditions.

Conclusions:

• Carbohydrate-based small molecules represent a promising new class of carbonic anhydrase inhibitors.
• Compounds 5 and 17 show significant potential for development as selective inhibitors targeting CA IX in hypoxic tumors.
• These findings support the advancement of carbohydrate-based CA inhibitors for future in vivo cancer therapy applications.